Aclaris Therapeutics Shares Sink After Atopic Dermatitis Treatment Misses Primary Endpoint
By Connor HartShares of Aclaris Therapeutics fell after the company said its investigational treatment for various inflammatory conditions failed to meet its primary or secondary endpoints in a recent midstage trial.The stock declined 8.7% to $3.58 shortly after Monday's opening bell. Despite the l…